Table 2.
Number (%) of Patients With Treatment-Related Adverse Events
| Lidocaine Patch 5% (n = 52), n (%) | Naproxen 500 mg Twice Daily (n = 48), n (%) | |
|---|---|---|
| Patients reporting AEs, n (%) | 13 (25.0) | 13 (27.1) |
| Patient withdrawals due to AEs | 3 (33.3) | 2 (14.3) |
| Patients reporting at least 1 TRAE (%) | 2 (3.8) | 7 (14.6) |
| TRAEs categorized by body system* | ||
| Nervous system disorders | 0 | 2 (4.2) |
| Dysgeusia | 0 | 1 |
| Loss of appetite | 0 | 1 |
| Gastrointestinal disorders | 1 (1.9) | 7 (14.6) |
| Nausea | 0 | 3 |
| Dyspepsia | 1 | 3 |
| Gastroesophageal reflux disease | 1 | 0 |
| Frequent bowel movements | 0 | 1 |
| Skin disorders/application site | 1 (1.9) | 0 |
| Rash | 1 | 0 |
*
Body system totals are not necessarily the sum of the individual adverse events because a patient may have reported 2 or more different adverse events in the same body system.
TRAE = treatment-related adverse event